Dr. Qayed serves as Associate Professor in the Department of Pediatrics at Emory University School of Medicine. She is an attending physician in Pediatric Hematology/Oncology and Bone Marrow Transplantation and Medical Director of the Cellular Therapy Laboratory at Children's Healthcare of Atlanta.
Her research interests include developing more effective prophylaxis/ treatment against graft versus host disease (GVHD) in patients undergoing allogeneic blood and marrow transplant and incorporating biomarkers for early diagnosis. Dr. Qayed's current work focuses on establishing and validating biomarkers in acute GVHD, including the role of microbiome alterations in GVHD and infections post transplantation, and investigating the use of mesenchymal stromal cells for the prevention and treatment of GVHD.
Qayed M, Ahn KW, Kitko CL, Johnson MH, Shah NN, Dvorak C, Mellgren K, Friend BD, Verneris MR, Leung W, Toporski J, Levine J, Chewning J, Wayne A, Kapoor U, Triplett B, Schultz KR, Yanik GA, Eapen M. A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation. Blood. 2021 Feb 18;137(7):983-993. doi: 10.1182/blood.2020009342. PMID: 33206937.
Watkins B, Qayed M, McCracken C, Bratrude B, Betz K, Suessmuth Y, Yu A, Sinclair S, Furlan S, Bosinger S, Tkachev V, Rhodes J, Tumlin AG, Narayan A, Cribbin K, Gillespie S, Gooley TA, Pasquini MC, Hebert K, Kapoor U, Rogatko A, Tighiouart M, Kim S, Bresee C, Choi SW, Davis J, Duncan C, Giller R, Grimley M, Harris AC, Jacobsohn D, Lalefar N, Norkin M, Farhadfar N, Pulsipher MA, Shenoy S, Petrovic A, Schultz KR, Yanik GA, Waller EK, Levine JE, Ferrara JL, Blazar BR, Langston A, Horan JT, Kean LS. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. J Clin Oncol. 2021 Jan 15:JCO2001086. doi: 10.1200/JCO.20.01086. Epub ahead of print. PMID: 33449816.
Qayed M, Wang T, Hemmer MT, et al. Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. Biol Blood Marrow Transplant. 2018;24(3):521-528. doi:10.1016/j.bbmt.2017.11.004
Chinnadurai R, Rajan D, Qayed M, et al. Potency Analysis of Mesenchymal Stromal Cells Using a Combinatorial Assay Matrix Approach. Cell Rep. 2018;22(9):2504-2517. doi:10.1016/j.celrep.2018.02.013
Novartis CTL019-2205B – 10/1/2015-5/11/2036
Long term follow up of patients exposed to lentiviral-based CD19 directed CAR-T cell therapy
Peach Bowl LegACy Fund – 03/24/2020-12/31/2020
CD19/22 CARPOOL: Phase I trial of CD19/22 Chimeric Antigen Receptor Protocol with Objective of Tolerability in Relapsed/Refractory B-ALL